Looking for Paclitaxel found 17 matches
|
Open monograph to display formulary status |
BNF Category |
|
Paclitaxel
|
Malignant disease and immunosuppression - Taxanes - 08.01.05
|
|
Paclitaxel - Albumin Bound Formulation
(Abraxane®)
|
Malignant disease and immunosuppression - Taxanes - 08.01.05
|
|
Atezolizumab
|
Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
|
|
Gemcitabine
|
Malignant disease and immunosuppression - Antimetabolites - 08.01.03
|
|
Pembrolizumab
(Keytruda®)
|
Malignant disease and immunosuppression - Other antineoplastic drugs - 08.01.05
|
|
Links Link to Drug Section Link to document |
MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error (08.01.05)
|
MHRA Drug Safety Update (Jan 2022): Paclitaxel formulations (conventional and nab-paclitaxel): caution required due to potential for medication error (08.01.05)
|
NICE TA284:Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer (08.01.05)
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.05)
|
NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.02)
|
NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer (08.01.03)
|
NICE TA476 Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (08.01.05)
|
NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer (08.01.05)
|
NICE TA639: Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer (08.01.05)
|
NICE TA770: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (08.01.05)
|
|
|